Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Group adds pharmacology expertise to BD team with recruitment of Dr David Loczenski

Dr David Loczenski has been appointed as Business Development Manager to promote the in vivo pharmacology and consultancy services offered by RenaSci.

David takes on the business development role after working for 2 years at RenaSci as a project leader within the metabolic disease group and has extensive in vivo pharmacology expertise with a specific edge in the field of obesity, Non-alcoholic fatty liver disease (NAFLD), insulin resistance and age-associated loss of muscle mass (sarcopenia).

One of David’s key tasks will be to ensure that the synergistic in vitro and in vivo services and drug discovery expertise offered by Sygnature Discovery and RenaSci are maximised for the benefit of the customers worldwide.

RenaSci became part of the Sygnature Group in July 2018 following several successful project collaborations with joint clients. Sygnature and RenaSci were amongst the first companies to be established at BioCity Nottingham, the R&D site where Boots Pharmaceuticals discovered ibuprofen. The strategic acquisition of RenaSci by Sygnature stemmed from a long-standing mutual respect between the organisations and the firm belief by Sygnature that combining the two companies would be beneficial not only to their customers, but ultimately to patients with considerable unmet medical need in abuse and dependence, CNS disorders, obesity, diabetes, Nonalcoholic steatohepatitis (NASH) and kidney disease.

David commented: “I’m looking forward to the opportunity to apply my scientific knowledge to a client facing environment and the being part of the integration of two world-class research companies.”

Dr Sharon Cheetham, Assistant Professor and Executive Director at RenaSci said: “Bringing together two highly-complementary businesses is helped by a strong shared focus on high-quality science and delivering new and efficacious drugs to patients. I’m excited to have David play a key role in the unified offering to the market and the expansion of the in vivo team to better serve our clients in the drug discovery and pre-clinical sector.”

Dr Paul Clewlow, Sygnature Discovery’s Senior Vice President, Business Development, and a member of the Board at Sygnature and RenaSci, commented: “It’s great to have David join the business development team at Sygnature Group. He will work closely with our colleagues at both RenaSci and Sygnature to convey the enhanced capabilities and expertise we offer to clients and identify new in vivo pharmacology capabilities that will complement and augment our current integrated offering. His deep in vivo pharmacology know-how will greatly benefit the dialogue with both current and prospect customers”.

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.